Immune Deficiency Clinical Trials

7 recruiting

Immune Deficiency Trials at a Glance

22 actively recruiting trials for immune deficiency are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in St Louis, Philadelphia, and Baltimore. Lead sponsors running immune deficiency studies include New York Medical College, National Institute of Allergy and Infectious Diseases (NIAID), and Columbia University.

Browse immune deficiency trials by phase

Treatments under study

About Immune Deficiency Clinical Trials

Looking for clinical trials for Immune Deficiency? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immune Deficiency trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immune Deficiency clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting

Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

Primary Immune Deficiency
National Institute of Allergy and Infectious Diseases (NIAID)5,000 enrolled7 locationsNCT00246857
Recruiting

Evaluation of Patients With Immune Function Abnormalities

Chronic Granulomatous Disease (CGD)X-Linked Severe Combined Immune Deficiency (XSCID)Leukocyte Adhesion Deficiency 1 (LAD)+1 more
National Institute of Allergy and Infectious Diseases (NIAID)3,500 enrolled1 locationNCT00128973
Recruiting
Phase 1Phase 2

Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)

Viral InfectionPrimary Immune Deficiency Disorder
New York Medical College40 enrolled7 locationsNCT04197596
Recruiting
Phase 1Phase 2

Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector

Adenosine Deaminase Severe Combined Immune Deficiency
University of California, Los Angeles20 enrolled1 locationNCT05432310
Recruiting
Not Applicable

WiseApp for Spanish Speakers Living With HIV

HIV InfectionsAcquired Immune Deficiency SyndromeSexually Transmitted Diseases, Viral
Columbia University248 enrolled2 locationsNCT05398185
Recruiting

Biologics And Clinical Immunology Cohort at Sinai

Autoimmune DiseasesImmunological DiseasePrimary Immune Deficiency
Icahn School of Medicine at Mount Sinai800 enrolled1 locationNCT04784364
Recruiting

Allergy and Immunology Natural History Study

Immune DeficiencyImmune Dysregulation DisorderAllergic Inflammation
Columbia University10,000 enrolled1 locationNCT05584488
Recruiting
Not Applicable

HIV Suicide Prevention With AI-DBT

HIVSuicidal Ideation and BehaviorAIDS (Acquired Immune Deficiency Syndrome)
Rutgers, The State University of New Jersey50 enrolled2 locationsNCT07339189
Recruiting
Not Applicable

Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy

Solid TumorHematologic MalignancySickle Cell Disease+3 more
Washington University School of Medicine60 enrolled1 locationNCT06689800
Recruiting
Phase 2

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

Dyskeratosis CongenitaFanconi AnemiaBone Marrow Failure+7 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins27 enrolled1 locationNCT04232085
Recruiting

Umbilical Cord Blood Transplantation From Unrelated Donors

Solid TumorMultiple MyelomaAcute Leukemia+7 more
University of Rochester30 enrolled1 locationNCT03016806
Recruiting

Early Life Malnutrition, Environmental Enteric Dysfunction and Microbiome Trajectories

Environmental Enteric DysfunctionMalnutrition in ChildrenMalnutrition (Calorie)+10 more
University of Zimbabwe368 enrolled1 locationNCT07195006
Recruiting
Phase 2

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

AdenovirusPrimary Immune Deficiency Disorder
New York Medical College20 enrolled10 locationsNCT03266627
Recruiting
Phase 2

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

Cytomegalovirus InfectionsPrimary Immune Deficiency Disorder
New York Medical College20 enrolled9 locationsNCT03266640
Recruiting
Phase 2

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Epstein-Barr Virus InfectionsPrimary Immune Deficiency Disorder
New York Medical College20 enrolled8 locationsNCT03266653
Recruiting
Phase 2

TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Metabolic DiseasePrimary Immune Deficiency Disorders
Johns Hopkins All Children's Hospital17 enrolled1 locationNCT04414046
Recruiting

Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform

Myelodysplastic SyndromesShwachman-Diamond SyndromeSDS+24 more
Shwachman-Diamond Syndrome Alliance Inc8,000 enrolled1 locationNCT06999954
Recruiting

X-linked Moesin Associated Immunodeficiency

DiagnosisInfectionsImmune Deficiency+1 more
Institut National de la Santé Et de la Recherche Médicale, France16 enrolled10 locationsNCT06278337
Recruiting

COVID-19 in PID Survey

COVIDPrimary Immune Deficiency
Imagine Institute200 enrolled1 locationNCT04459689
Recruiting
Phase 2

Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults

Immune Deficiency
Qu Biologics Inc.72 enrolled1 locationNCT05421325